nach oben

Erschienen in:

01.06.2010 | Brief Report

Two-stage case–control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk

verfasst von: Chuanzhong Ye, Alicia Beeghly-Fadiel, Wei Lu, Jirong Long, Xiao Ou Shu, Yu-Tang Gao, Wei Zheng, Qiuyin Cai

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Aberrant DNA methylation of CpG islands is a common epigenetic alteration found in cancers. DNA methylation is typically mediated by DNA methyltransferases (DNMTs). Only two studies have evaluated DNMT-1 and/or DNMT-3B gene polymorphisms in relation to breast cancer risk, and results have been inconsistent. We comprehensively evaluated genetic variations in the DNMT-1 and DNMT-3B genes with breast cancer risk among the participants of the Shanghai Breast Cancer Study, a large-scale, two-stage, case–control study. Of the 25 SNPs in the DNMT-1 and DNMT-3B genes analyzed, only one (rs8101866) reached a normal significance level (P = 0.042). This association, however, was no longer statistically significant after adjustment for multiple comparisons. Our data suggest that there is no apparent association of common DNMT-1 and DNMT-3B polymorphisms with the risk of breast cancer among Chinese women.

Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054CrossRefPubMed

Fan H, Zhang F, Hu J, Liu D, Zhao Z (2008) Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case–control study. J Exp Clin Cancer Res 27:24CrossRefPubMed

Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Cho YL, Jung TH, Park JY (2005) DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26:403–409CrossRefPubMed

Liu Z, Wang L, Wang LE, Sturgis EM, Wei Q (2008) Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case–control study. Cancer Lett 268:158–165CrossRefPubMed

Montgomery KG, Liu MC, Eccles DM, Campbell IG (2004) The DNMT3B C->T promoter polymorphism and risk of breast cancer in a British population: a case–control study. Breast Cancer Res 6:R390–R394CrossRefPubMed

Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q (2002) A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 62:4992–4995PubMed

Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ (2005) Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep 14:569–573PubMed

Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, Conroy D, Luben R, Perkins B, Easton DF, Dunning AM, Esteller M, Ponder BA (2006) Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 27:1661–1669CrossRefPubMed

Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, Sellers TA, Kushi LH, Ruan Z, Bostick RM, Jin F, Zheng W (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai breast cancer study. Int J Cancer 87:295–300CrossRefPubMed

10.

Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41(32):4–328

11.

International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef

12.

de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, Ke X, Monsuur AJ, Whittaker P, Delgado M, Morrison J, Richardson A, Walsh EC, Gao X, Galver L, Hart J, Hafler DA, Pericak-Vance M, Todd JA, Daly MJ, Trowsdale J, Wijmenga C, Vyse TJ, Beck S, Murray SS, Carrington M, Gregory S, Deloukas P, Rioux JD (2006) A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 38:1166–1172CrossRefPubMed

13.

Hardenbol P, Yu F, Belmont J, Mackenzie J, Bruckner C, Brundage T, Boudreau A, Chow S, Eberle J, Erbilgin A, Falkowski M, Fitzgerald R, Ghose S, Iartchouk O, Jain M, Karlin-Neumann G, Lu X, Miao X, Moore B, Moorhead M, Namsaraev E, Pasternak S, Prakash E, Tran K, Wang Z, Jones HB, Davis RW, Willis TD, Gibbs RA (2005) Highly multiplexed molecular inversion probe genotyping: over 10, 000 targeted SNPs genotyped in a single tube assay. Genome Res 15:269–275CrossRefPubMed

14.

Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S (2003) Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 105:527–532CrossRefPubMed

15.

Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33:61–65CrossRefPubMed

16.

Girault I, Tozlu S, Lidereau R, Bieche I (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9:4415–4422PubMed

17.

Wang L, Rodriguez M, Yue P, Sun SY, Hong WK, Mao L (2001) Polymorphism in DNMT3B6 promoter region and lung cancer risk. Proc Am Assoc Cancer Res 42:863

18.

Chang KP, Hao SP, Liu CT, Cheng MH, Chang YL, Lee YS, Wang TH, Tsai CN (2007) Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case–control study. Oral Oncol 43:345–351CrossRefPubMed

Titel: Two-stage case–control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk
verfasst von: Chuanzhong Ye
Alicia Beeghly-Fadiel
Wei Lu
Jirong Long
Xiao Ou Shu
Yu-Tang Gao
Wei Zheng
Qiuyin Cai
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0569-9

Springer Medizin

Two-stage case–control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Expression of TGF-β signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics

Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

High levels of uPA and PAI-1 predict a good response to anthracyclines

Metabolic profile, physical activity, and mortality in breast cancer patients

Impact of multiple caregiving roles on elevated depressed mood in early-stage breast cancer patients and same-age controls

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie